Our top coverage from this year’s San Antonio Breast Cancer Symposium (SABCS) included updated data on tamoxifen and trastuzumab deruxtecan, treatments long proven effective in the breast cancer space.
Our top coverage from this year’s San Antonio Breast Cancer Symposium (SABCS) included updated data on tamoxifen and trastuzumab deruxtecan, treatments long proven effective in the breast cancer space; the importance of not forgetting breast cancer can also occur in male patients; and improving quality of care by utilizing data on patient-reported outcomes.
These are your SABCS 2022 conference highlights, and click here for all of our coverage from the conference.
10-Year Babytam Data Show Reduced-Dose Tamoxifen Still Producing Positive Results
The ongoing TAM-01 study is currently investigating a 5-mg daily dose of tamoxifen, known as babytam, and the data presented at SABCS 2022 serve as an update to data presented at the conference in 2018. With a primary end point of incidence of invasive breast cancer, the 10-year data bear out a 32% reduced risk of ipsilateral breast cancer and a 64% reduced risk of contralateral breast cancer. The overall low risk of death, 0.6% at 10 years, is one of the factors supporting treatment de-escalation for ductal carcinoma in situ.
Dr Lola Fayanju Shares How Providers Can Leverage PROs to Improve Breast Cancer Care
The American Journal of Managed Care®(AJMC®) sat down with Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS, chief of breast surgery and surgical director for the Rena Rowan Breast Center at Abramson Cancer Center of Penn Medicine. In this interview, she addresses the importance of incorporating patient-reported outcomes (PROs) data when striving to improve patient quality of life and initiatives that can help to overcome barriers to care access and facilitate guideline-concordant care.
DESTINY-Breast Data Add to Accolades for Trastuzumab Deruxtecan
Findings presented from the DESTINY-Breast02 and DESTINY-Breast03 trials continue the stream of positive results from investigations of trastuzumab deruxtecan (T-DXd), the human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate, in the setting of HER2-positve metastatic breast cancer. DESTINY-Breast02 is investigating outcomes among patients randomized to T-DXd vs physician’s choice of trastuzumab/capecitabine or lapatinib/ capecitabine, and DESTINY-Breast03 is exploring the aftereffects of randomization to T-DXd or trastuzumab emtansine.
Dr Jose P. Leone Highlights the Importance of Breast Cancer Awareness for Male Patients
AJMC® also spoke to Jose P. Leone, MD, director of the program for breast cancer in men and assistant professor of medicine at Harvard medical school, for a discussion on the evolving treatment landscape for men who have breast cancer, including current treatment standards and how these mirror treatment choices in female patients. He also explored some of the unique challenges inherent in treating men who have breast cancer and increasing awareness of the disease among oncologists and health care professionals; in particular, the importance of screening mammograms.